From Molecules to Meaning

The perspective of a patient, scientist and advocate

Dr Colette ANDRÉE

Chemist · Pharmacist · Neuroscientist · Advocate

EFMC Medicinal Chemistry
International Symposium
on Medicinal Chemistry
Basel, Switzerland
September 6-10, 2026

From experience to molecules to meaning

ATTACK	TIME
TREATMENT	LIFE

A call for action.

Imagine tomorrow is the most important presentation of your career

LIGHT	SOUND
LANGUAGE	PAIN

Nothing visible.

Everything altered

Migraine much more than pain

PRODROME

AURA

HEADACHE

POSTDROME

Before ...during...after...

and ...in between

Invisible does not mean absence

>1 BILLION	#3
COMMON	DISABLING

Common does not mean simple

Thirty substances. One life

NSAIDs	TRIPTANS
PREVENTIVES	CGRP

Benefit is always weighed against burden



CGRP-Targeted Migraine Therapies

GRATITUDE

PROGRESS

UNANSWERED

BIOLOGY

60% fewer attacks

40% remains…

The unfinished chemistry of migraine

CGRP PATHWAY
Some patients still respond insufficiently.

POSTDROME
No established phase-specific therapy.

AURA · SENSITISATION · CHRONIFICATION
Open biological targets remain.

GENETIC HETEROGENEITY
Barely translated into genuinely personalised treatment.

UNDER-REPRESENTED PATIENTS
Narrower evidence and choices for children, pregnancy and major comorbidities.

The endpoint is valuable life

WORK	FAMILY
PLANS	TRUST

Not only fewer days . More life.

Better questions changed therapy

OBSERVATION	SELECTIVITY
PATHWAYS	PRECISION

Progress changes what patients dare to plan.



Connect mechanism with meaning

DIGNITY	LISTEN
CURIOSITY	COMPASSION

Let each sharpen the other.

Behind every molecule is a person hoping for one more usable day.

Thank you for helping turning molecules into meaning.

Dr Colette ANDRÉE

Scientific grounding for the factual claims*

01 WHO · Migraine and other headache disorders · 2025

02 GBD 2021 Nervous System Disorders Collaborators · Lancet Neurology · 2024

03 Ashina M · Migraine · New England Journal of Medicine · 2020

04 International Headache Society · ICHD-3 · Cephalalgia · 2018

05 **Reuter U et al · TEMPLE phase 3b trial · Lancet Neurology · 2026**

**selected sources*